Hepatitis B
Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver
- Details
- Category: HBV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
N-acetylcysteine (NAC) administered during recovery of a liver from a deceased donor can help reduce damage during transplantation and increase survival of the liver graft in the recipient, according to a study published in the February 19, 2013, issue of Liver Transplantation.
Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Details
- Category: Liver Transplant/Artificial Liver
- Published on Wednesday, 20 February 2013 00:00
- Written by Novartis
The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
HIV+ Less Likely to Respond to Hepatitis B Vaccine, but More Shots Increase Protection
- Details
- Category: HBV Prevention
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
Adults in Kenya responded as well overall to hepatitis B vaccination as people in high-income countries. People with HIV had poorer response, but this could be mostly overcome with repeated doses, according to a study described in the February 1, 2013, Journal of Infectious Diseases.
Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity
- Details
- Category: HBV Prevention
- Published on Friday, 11 January 2013 00:00
- Written by NIH
Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.
Chronic Hepatitis Cohort Study Sheds Light on Burden of Hepatitis B and C in U.S.
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 01 February 2013 00:00
- Written by Liz Highleyman
People born between 1945 and 1964 account for the highest proportion of hepatitis B and C cases, and these viruses are a significant cause of illness and death, according to an analysis described in the January 1, 2013, Clinical Infectious Diseases.
Researchers Discover Structure of Hepatitis B Antigen that Interferes with Immune Response
- Details
- Category: HBV Basic Science
- Published on Tuesday, 08 January 2013 00:00
- Written by NIH
Researchers from the University of Oxford and the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases have determined the crystal structure of the hepatitis B "e" antigen (HBeAg), which plays a role in immune tolerance and chronic hepatitis B virus (HBV) infection, according to a study published in the January 8, 2013, issue of the journal Structure. These findings may aid the development of new therapies that improve immune response against the virus.
Heavy Alcohol Use Increases Liver Cancer Risk for People with Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Thursday, 24 January 2013 00:00
- Written by Liz Highleyman
Hepatitis B patients with liver cirrhosis who consumed large amounts of alcohol were more likely to develop hepatocellular carcinoma (HCC) than people who drank less, according to a report in the December 6, 2012, online edition of the Journal of Hepatology. However, antiviral treatment can help prevent liver cancer.
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
More Articles...
- FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate
- AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
- AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
Web Design and Development by